GLP-1 Receptor Agonists Show Promise for Right Heart Failure in PAH
Although patients with pulmonary arterial hypertension (PAH) treated with glucagon-like peptide-1 (GLP-1) receptor agonists and SGLT2 inhibitors have comparable mortality rates, GLP-1 receptor agonists...
GLP-1 Receptor Agonists May Increase Survival in Patients With T2DM and OSA
Glucagon-like peptide-1 (GLP-1) receptor agonists appear to reduce mortality in people with type 2 diabetes (T2DM). A new study of nearly 1.8 million patients...
Inhaled Dry Powder Treprostinil Shows Safety and Efficacy in PH-ILD
In patients with pulmonary hypertension-interstitial lung disease (PH-ILD), treatment with LIQ861 (YUTREPIA™, Liquidia Corporation), a novel inhaled dry powder formulation of treprostinil, appears to...
COPD Mortality Risk: Demographic Disparities in Hospitalized Patients
Thirty-day mortality outcomes for patients hospitalized for acute COPD exacerbations in the US appear to vary based on their demographics. Males are at elevated...